Camlin Fine Sciences Ltd vs Epigral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 22, 2026

Key Highlights

The Latest Trading Price of Camlin Fine Sciences Ltd is ₹ 118.65 as of 20 Mar 15:30 . The P/E Ratio of Camlin Fine Sciences Ltd changed from 35 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Epigral Ltd changed from 16 on March 2022 to 22.9 on March 2025 . This represents a CAGR of 9.38% over 4 years The Market Cap of Camlin Fine Sciences Ltd changed from ₹ 1782 crore on March 2021 to ₹ 3155 crore on March 2025 . This represents a CAGR of 12.10% over 5 yearsThe Market Cap of Epigral Ltd changed from ₹ 4045 crore on March 2022 to ₹ 8191 crore on March 2025 . This represents a CAGR of 19.29% over 4 years The revenue of Camlin Fine Sciences Ltd for the Dec '25 is ₹ 460.13 crore as compare to the Sep '25 revenue of ₹ 464.42 crore. This represent the decline of -0.92% The revenue of Epigral Ltd for the Dec '25 is ₹ 602.68 crore as compare to the Sep '25 revenue of ₹ 589.1 crore. This represent the growth of 2.31% The ebitda of Camlin Fine Sciences Ltd for the Dec '25 is ₹ -2 crore as compare to the Sep '25 ebitda of ₹ 28.7 crore. This represent the decline of -106% The ebitda of Epigral Ltd for the Dec '25 is ₹ 108.26 crore as compare to the Sep '25 ebitda of ₹ 133.8 crore. This represent the decline of -19.09% The net profit of Camlin Fine Sciences Ltd changed from ₹ -34.65 crore to ₹ -37.1 crore over 7 quarters. This represents a CAGR of 3.98% The net profit of Epigral Ltd changed from ₹ 85.87 crore to ₹ 39.11 crore over 7 quarters. This represents a CAGR of -36.20% The Dividend Payout of Camlin Fine Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Epigral Ltd changed from 5.88 % on March 2023 to 7.26 % on March 2025 . This represents a CAGR of 7.28% over 3 years .

About Camlin Fine Sciences Ltd

Camlin Fine Sciences Limited was originally incorporated on November 30, 1993 as a Private Limited Company with the name of 'Camlicon Consultants Private Limited'.
On June 1, 2006, the Company name was changed from Camlicon Consultants Private Limited to Camlin Fine Chemicals Private Limited.
As per the Scheme of Arrangement, the Fine Chemicals Division of Camlin Limited got demerged and transferred to the Company effective from July 01, 2006.
On August 11, 2006, the Company status was converted into Public Limited Company and the name was changed to Camlin Fine Chemicals Limited.
W.e.f. 27th August, 2011 name of the Company was changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited. The Company is one of the India's leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products.

About Epigral Ltd

Epigral Limited was erstwhile incorporated as 'Meghmani Finechem Limited' in 2007, which is engaged in manufacturing and selling of Chlor Alkali & its Derivatives and also in Trading of Agrochemical products.
The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern, through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021.
The Chlor-Alkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21.
The Company is now among the leading players in India's chlor alkali industry.
In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/- each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.

FAQs for the comparison of Camlin Fine Sciences Ltd and Epigral Ltd

Which company has a larger market capitalization, Camlin Fine Sciences Ltd or Epigral Ltd?

Market cap of Camlin Fine Sciences Ltd is 2,279 Cr while Market cap of Epigral Ltd is 3,676 Cr

What are the key factors driving the stock performance of Camlin Fine Sciences Ltd and Epigral Ltd?

The stock performance of Camlin Fine Sciences Ltd and Epigral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Camlin Fine Sciences Ltd and Epigral Ltd?

As of March 22, 2026, the Camlin Fine Sciences Ltd stock price is INR ₹118.65. On the other hand, Epigral Ltd stock price is INR ₹852.25.

How do dividend payouts of Camlin Fine Sciences Ltd and Epigral Ltd compare?

To compare the dividend payouts of Camlin Fine Sciences Ltd and Epigral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.